Edition:
United States

Loxo Oncology Inc (LOXO.O)

LOXO.O on Consolidated Issue listed on NASDAQ Global Market

233.50USD
18 Jan 2019
Change (% chg)

$0.25 (+0.11%)
Prev Close
$233.25
Open
$233.58
Day's High
$233.59
Day's Low
$233.25
Volume
1,541,340
Avg. Vol
729,943
52-wk High
$233.90
52-wk Low
$85.21

Chart for

About

Loxo Oncology, Inc. is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company's pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.... (more)

Overall

Beta: --
Market Cap(Mil.): $2,616.89
Shares Outstanding(Mil.): 29.85
Dividend: --
Yield (%): --

Financials

  LOXO.O Industry Sector
P/E (TTM): -- 69.71 33.71
EPS (TTM): -4.18 -- --
ROI: -31.65 8.99 14.48
ROE: -31.65 10.13 15.99

Lilly eyes more cancer deals, but wary of CAR-T, gene therapy

Eli Lilly and Co remains in the hunt for cancer drugs even after announcing an $8 billion purchase of Loxo Oncology this week, but it plans to remain on the sidelines when it comes to two of the hottest areas of drug development.

Jan 11 2019

REFILE-Lilly eyes more cancer deals, but wary of CAR-T, gene therapy

Jan 11 Eli Lilly and Co remains in the hunt for cancer drugs even after announcing an $8 billion purchase of Loxo Oncology this week, but it plans to remain on the sidelines when it comes to two of the hottest areas of drug development.

Jan 11 2019

Deals of the day-Mergers and acquisitions

Jan 11 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Friday: ** Twenty-First Century Fox said it does not plan to bid for any of the regional sports networks that Walt Disney Co may need to sell to win U.S. Justice Department's approval for its purchase of Fox's film and TV assets. ** Eli Lilly and Co remains in the hunt for cancer drugs even after announcing an $8 billion purchase of Loxo Oncology this week, but it plans to remain on the sideli

Jan 11 2019

Healthcare deals raise pulse of US lending in 2019

NEW YORK, Jan 11 (LPC) - Bankers are diagnosing another robust year for US healthcare lending. The first two big loans of 2019 are financing the acquisitions of pharmaceutical companies, including the largest ever tie-up in the sector, and more are expected.

Jan 11 2019

Lilly makes $8 billion bet on drugs for rare cancers with Loxo Oncology buy

Eli Lilly said on Monday it will buy Loxo Oncology Inc for $8 billion, an expensive bet on a pipeline of cancer drugs that target rare genetic mutations and the biggest acquisition in the drugmaker's 143-year history. The price represents a 68 percent premium to Loxo's Friday share price close, which some Wall Street analysts said was high for a company with only one drug on the market that it shares with a partner. | Video

Jan 07 2019

UPDATE 5-Lilly makes $8 bln bet on drugs for rare cancers with Loxo Oncology buy

Jan 7 Eli Lilly said on Monday it will buy Loxo Oncology Inc for $8 billion, an expensive bet on a pipeline of cancer drugs that target rare genetic mutations and the biggest acquisition in the drugmaker's 143-year history.

Jan 07 2019

Amazon and Netflix push Wall Street higher

Amazon.com Inc and Netflix fueled a second straight session of gains on Wall Street on Monday, as the resumption of U.S.-China trade talks helped ease concerns that have pummeled the market in recent months. | Video

Jan 07 2019

Lilly to buy Loxo Oncology for about $8 bln

Jan 7 Eli Lilly and Co said on Monday it would buy Loxo Oncology Inc for about $8 billion in cash.

Jan 07 2019

German stocks - Factors to watch on Nov. 27

BERLIN, Nov 27 The following are some of the factors that may move German stocks on Tuesday:

Nov 27 2018

Loxo, Bayer drug for cancers driven by rare mutation gets U.S. nod

A Loxo Oncology Inc drug shown to be effective against a wide variety of cancers driven by a single, rare genetic mutation has won U.S. approval, the Food and Drug Administration announced on Monday.

Nov 26 2018

Earnings vs. Estimates